You are here

  • Home
  • Archive
  • Volume 77, Issue 6
  • Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Article metrics

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

 

Online download statistics by month:

Online download statistics by month: March 2018 to March 2024

AbstractFullPdf
Mar 20182293322118
Apr 2018129715086
May 20181215167104
Jun 201869211562
Jul 20183765134
Aug 20183163321
Sep 20183574621
Oct 20183594329
Nov 20182353728
Dec 20182412514
Jan 20192642113
Feb 20192302711
Mar 20192063815
Apr 20192302313
May 20193183210
Jun 20191912211
Jul 2019204219
Aug 20191363111
Sep 20191563320
Oct 20192473319
Nov 20191283314
Dec 20191721812
Jan 2020143169
Feb 20202163317
Mar 20202162114
Apr 2020197138
May 2020214199
Jun 2020192158
Jul 20201811811
Aug 20201482414
Sep 20201822613
Oct 20202291614
Nov 2020186159
Dec 2020161175
Jan 20211181513
Feb 20212501612
Mar 2021244155
Apr 2021409189
May 20211991910
Jun 202127237
Jul 2021976
Aug 2021161211
Sep 2021302720
Oct 2021152127
Nov 2021259227
Dec 2021248217
Jan 2022169173
Feb 2022174510
Mar 2022356176
Apr 2022150103
May 2022247124
Jun 2022200183
Jul 20221892710
Aug 2022223217
Sep 2022220316
Oct 2022282196
Nov 20223301912
Dec 202211482
Jan 202318494
Feb 2023218141
Mar 2023291279
Apr 20232921610
May 20233312313
Jun 2023201127
Jul 202312693
Aug 2023160155
Sep 2023216122
Oct 2023436103
Nov 2023699197
Dec 2023251297
Jan 2024202359
Feb 2024203219
Mar 2024210278
Total2076322431089